During this webinar session, Dr Antonio Urbano Carrillo, Clinical Geneticist from UR Vistahermosa International Group, discussed a crucial topic of embryo aneuploidy and its implications for IVF treatments.
Chromosomes are fundamental units of genetic information in humans. Karyotyping reveals their distribution in 23 pairs. Pairs 1 to 22 are autosomes, common to both sexes. The 23rd pair consists of sex chromosomes, differentiating males (XY) from females (XX). This male karyotype showcases the normal 46 chromosomes, divided into 23 pairs. Conversely, individuals can possess variations such as trisomies, which result in chromosomal disorders like Down syndrome.
Karyotyping provides a visual insight into the genetic makeup of an individual.
The typical chromosomal makeup is 46, with 23 pairs, but exceptions arise due to errors in cell division. Trisomy, indicated by 3 chromosomes in a pair, can lead to conditions like Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or Patau syndrome (Trisomy 13). Monosomy, with a chromosome missing, also exists. These deviations can impact viability and pregnancy outcomes, often leading to miscarriages or implantation failure.
Maternal age plays a crucial role in chromosomal abnormalities. Advanced maternal age increases the likelihood of aneuploidy, where embryos have an abnormal number of chromosomes. This phenomenon intensifies the risks of miscarriage and chromosomal syndromes. Graphical depictions underscore how fertility decreases and miscarriage rates rise with age. However, genetic screening like preimplantation genetic testing (PGT) can aid in embryo selection, improving IVF success rates.
PGT-A enables the selection of viable embryos for transfer, enhancing the chances of successful pregnancies. Trisomies and monosomies can be detected, allowing the prioritization of healthier embryos for implantation. PGT’A’s benefits extend to couples with recurrent miscarriages, advanced maternal age, or male infertility due to azoospermia. Moreover, PGT-A (aneuploidy screening) and PGT-M (monogenic disorder screening) have revolutionized assisted reproductive technology.
PGT offers couples a powerful tool to optimize their chances of conceiving a healthy baby.
Non-invasive screening techniques like NiPGT-A look promising. Similar to non-invasive prenatal tests (NIPT), this approach minimizes risks associated with embryo biopsies. Concordance rates between these methods and traditional PGT demonstrate the effectiveness of these innovations. Such techniques hold potential for further refining embryo selection and reducing the time to successful pregnancies.
In conclusion, understanding chromosomal structure, variations, and screening techniques like PGT can greatly influence pregnancy outcomes. As science progresses, these tools offer new ways to ensure healthy pregnancies and births.
Embryo testing is typically performed at reputable and reliable laboratories. The field is comprised of a small number of trustworthy facilities. If a laboratory lacks credibility, it could hinder a career in this field. Practitioners continually enhance their skills and maintain a strong reputation.
False positive and false negative outcomes exist in PGT-A, but the rates are generally low. While no test is perfect, the likelihood of both false positive and false negative results is minimized in PGT-A. Positive predictive value and negative predictive value are crucial metrics here, and the false positive rate is slightly higher than the false negative rate.
Experimental biopsies pose a minimal risk to embryo quality. The quality of the embryo is a vital consideration. Poor-quality embryos are more likely to be affected. The impact of the biopsy on the embryo is negligible, and the risk is minor.
Considering your history and diagnosis, if the PGT-A results indicate that all your embryos are unviable, it might be time to think about egg donation. If you have 1 viable embryo, transferring it is a good option. An egg donor could be considered if needed.
Despite your donor’s age, testing your last embryo might be beneficial. This is especially true if you’ve had implantation failures before. The testing provides valuable information for decision-making.
Transferring an aneuploid embryo doesn’t directly increase the risk of an ectopic pregnancy. The specific type of embryo that relates to ectopic pregnancies is different from aneuploid embryos. It’s a good idea to discuss any concerns with your doctor.
